Introduction
Penicillin-resistant Streptococcus pneumoniae has caused serious therapeutic problems. 1, 2 The frequency of penicillin resistance in S. pneumoniae, a significant cause of human bacterial pneumonia, has increased in virtually every part of the world. In Japan, about 40% of S. pneumoniae are reported to be penicillin-resistant. 3 Increasingly, these pathogens are also becoming resistant to macrolides.
Recent years have seen great interest in the use of quinolones for the treatment of respiratory tract infections. Potential advantages of this class of agents include good absorption following oral administration, good penetration into various tissues, and a broad spectrum of antibacterial activity. Among commercially available quinolones, sparfloxacin and levofloxacin have demonstrated better activity against S. pneumoniae than have ofloxacin or ciprofloxacin. AM-1155 has a broad spectrum of activity and shows greater activity than ofloxacin or ciprofloxacin against Gram-positive bacteria, including S. pneumoniae. 4, 5 In this study, the in-vitro activity of AM-1155 against clinical isolates of S. pneumoniae was compared with that of levofloxacin, sparfloxacin, erythromycin, and penicillin G. The efficacy of AM-1155 against experimental murine pneumonia with penicillin-resistant pathogens was also evaluated, using survival rate and clearance of bacteria from the lungs as criteria.
Materials and methods

Antibacterial agents
Quinolones were obtained as follows: AM-1155 from Kyorin Pharmaceutical Co. Ltd (Tochigi, Japan), levofloxacin from Daiichi Pharmaceutical Co. Ltd (Tokyo, Japan), and sparfloxacin from Dainippon Pharmaceutical Co. Ltd (Osaka, Japan). Penicillin G and erythromycin were purchased from commercial sources.
Bacteria
Forty-eight clinical isolates of S. pneumoniae (including the S. pneumoniae strain intermediately resistant to penicillin, TUM741, used for the study of in-vivo efficacy) were obtained from the Toho University School of Medicine.
Determination of MICs
MICs of the test drugs were determined by the standard microdilution method 6 using cation-adjusted Mueller- Hinton broth (MHB, Difco, Detroit, MI, USA) supplemented with 5% lysed horse blood. MICs were defined as the lowest drug concentrations that inhibited visible growth of bacteria.
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In-vivo efficacy
CBA/J male mice (5 weeks old, Charles River Japan, Kanagawa, Japan) were anaesthetized by intramuscular injection of a mixture of 6 mg/kg of ketamine (Sankyo, Tokyo, Japan) and 1 mg/kg of xylazine (Bayer Japan, Tokyo, Japan). Anaesthetized mice were infected intranasally with a bacterial suspension of S. pneumoniae TUM741 according to the method of Tateda and colleagues. 7 Drugs were administered three times at 4 h intervals, beginning 36 h after infection. Quinolones were administered orally. Each dose was 60 mg/kg. Penicillin G was administered subcutaneously at the same dose. Viable bacterial cells in the lungs were counted 18 h after the final dosage. The significance of differences in bacterial counts was tested by Tukey's method. In another experiment, mice were treated on the same schedule using doses of 100 mg/kg and the number of surviving mice was recorded for 10 days.
Results and discussion Figure 1 shows the susceptibility of clinical isolates of S. pneumoniae to various drugs. MICs of penicillin G ranged from 0.008 to 4 mg/L. Twenty-seven (56%) isolates had an MIC of 0.1 mg/L and were thus classified as penicillin resistant. Erythromycin inhibited 50% and 90% of the isolates tested at concentrations of 2 and 4 mg/L, respectively. Thus, more than 50% of these clinical isolates were erythromycin-resistant.
AM-1155 showed potent activity against S. pneumoniae, including penicillin-resistant isolates, with an MIC 90 of 0.25 mg/L. The MIC 90 s of sparfloxacin and levofloxacin were 0.25 and 1 mg/L, respectively. Thus, the in-vitro activity of AM-1155 was comparable with that of sparfloxacin and four times higher than that of levofloxacin. AM-1155 also demonstrated potent activity against penicillin-resistant and erythromycin-resistant isolates, which showed no cross-resistance to AM-1155. Our results are consistent with those of Wakabayashi & Mitsuhashi 5 and of Hosaka and colleagues, 4 who reported that AM-1155 shows activity comparable with that of sparfloxacin against S. pneumoniae.
Even more significantly, susceptibility to AM-1155 did not differ among isolates susceptible to penicillin (MICs 8 with regard to other quinolones such as sparfloxacin and temafloxacin, suggests that AM-1155 may have the same therapeutic efficacy against highly penicillin-resistant S. pneumoniae strains as against those showing intermediate resistance. Figure 2 shows the in-vivo efficacy of AM-1155, as measured by viable bacterial counts in lungs, against experimental pneumonia caused by S. pneumoniae TUM741 (intermediately resistant to penicillin; MIC 1 mg/L), compared with that of other drugs. Viable cell counts in untreated mice were 5.7 0.6 (mean S.D.) log cfu/lungs. Three oral doses of 60 mg/kg of AM-1155 reduced the bacterial counts to about 1% (3.7 0.8 log cfu/lungs) of those in untreated mice.
The number of viable bacteria in the lungs of mice treated with levofloxacin, sparfloxacin, and penicillin G were 4.3 0.7, 3.4 1.0, and 3.8 0.4 log cfu/lungs, respectively. The efficacy of AM-1155 was almost equal to that of sparfloxacin and was superior to that of levofloxacin. None of the differences in efficacy among these three quinolones was statistically significant. However, Azoulay-Dupuis and colleagues 9 reported that sparfloxacin is more effective than ciprofloxacin against pneumonia caused by either penicillin-susceptible or penicillin-resistant isolates of S. pneumoniae. These data indicate that the in-vitro activities of the new quinolones are reflected in their in-vivo efficacies. Furthermore, oral administration of AM-1155 showed the same efficacy as subcutaneous administration of the same dose of penicillin G.
Miyazaki and colleagues 10 and Tateda and colleagues 7 have reported that penicillin G is not efficacious against strain TUM741 at doses of 2.5 mg/kg, but that at doses of 10 mg/kg or more it decreases the number of viable bacteria in the lungs of animals in a dose-dependent manner. Penicillin G doses of 40 mg/kg are required to achieve efficacy comparable with that against a penicillin-susceptible strain. Furthermore Azoulay-Dupuis and colleagues 9 compared sparfloxacin with the penicillin-class antibiotic amoxycillin at equivalent subcutaneous doses: sparfloxacin offered similar efficacy against penicillin-resistant strains.
The efficacy of three 100 mg/kg doses of the test drugs was also examined, as measured by 10-day survival rates. Untreated mice all died by day 10, as did those treated with levofloxacin. Day-10 survival rates in mice treated with sparfloxacin were 20%, while 30% of the mice treated with AM-1155 or penicillin G survived.
These data suggest that AM-1155 might be a useful tool in the treatment of infection by S. pneumoniae, including penicillin-resistant strains. 
